Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

4(50.0%)

Phase 2

2(25.0%)

Phase 3

2(25.0%)

8Total

Phase 1(4)

Phase 2(2)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT03921541Phase 3Completed

Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency

Role: lead

NCT05154890Phase 1Terminated

A Multiple Ascending Dose Study of ACN00177 (Pegtarviliase) in Subjects With CBS Deficiency

Role: lead

NCT03378531Phase 2Completed

A Study of AEB1102 (Pegzilarginase) in Patients With Arginase I Deficiency

Role: lead

NCT05676853Phase 3Terminated

A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency

Role: lead

NCT02561234Phase 1Completed

A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors

Role: lead

NCT03371979Phase 1Completed

Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer

Role: lead

NCT02488044Phase 1Completed

A Phase 1/2 Study of AEB1102 in Patients With Arginase I Deficiency

Role: lead

NCT02732184Phase 2Completed

A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS

Role: lead

All 8 trials loaded